Abstract:Disulfiram (DSF), an alcohol-aversion drug, has been explored for cancer treatment. Copper diethyldithiocarbamate (Cu(DDC)2) complex formed by DSF and copper ions is a major active ingredient for its anticancer activity. Direct administration of Cu(DDC)2 is a promising strategy to enhance the anticancer efficacy of DSF. However, efficient drug delivery remains a significant challenge for Cu(DDC)2 and hinders its clinical use. In this study, we developed a facile stabilized metal ion ligand complex (SMILE) method to prepare Cu(DDC)2 nanoparticles (NPs). The SMILE method could prepare Cu(DDC)2 NPs with different types of stabilizers including 1,2-distearoyl- sn-glycerol-3-phosphoethanolamine-poly(ethylene glycol) (PEG) 2000, d-α-tocopherol PEG 1000 succinate, methoxy PEG 5000- b-poly(l-lactide) 5000, and other generally recognized as safe excipients approved by the US Food and Drug Administration. The optimized formulations demonstrated excellent drug-loading efficiency (close to 100%), high drug concentrations (increased drug concentration by over 200-fold compared to the traditional micelle formulation), and an optimal particle size in the sub-100 nm range. Cu(DDC)2 NPs exhibited outstanding stability in serum for 72 h and can also be stored at room temperature for at least 1 month. The anticancer effects of Cu(DDC)2 NP formulations were determined by multiple assays including 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay, colony-forming assay, calcein-AM/propidium iodide staining, and others. Cu(DDC)2 NPs showed excellent activity against drug-resistant prostate cancer cells and other cancer cells with a half-maximal inhibitory concentration (IC50) of around 100 nM. Our study also demonstrated that Cu(DDC)2 NPs induced cell death in drug-resistant prostate cancer cells (DU145-TXR) through paraptosis, which is a nonapoptotic cell death. To our best knowledge, the SMILE method provides, for the first time, a simple yet efficient process for generating Cu(DDC)2 NPs with high drug concentration, excellent loading efficiency, and desirable physicochemical properties. This method could potentially address drug delivery challenges of DSF/copper-based chemotherapy and facilitate its clinical translation.

Disulfiram-loaded CuO2 nanocarriers for enhanced synergistic chemodynamic chemotherapy

Co-delivery of a tumor microenvironment-responsive disulfiram prodrug and CuO2 nanoparticles for efficient cancer treatment

Polydopamine-Modified Copper Coordination Mesoporous Silica Nanoparticles Loaded with Disulfiram for Synergistic Chemo-Photothermal Therapy

Nanomedicine-based Disulfiram and Metal Ion Co-Delivery Strategies for Cancer Treatment

Tumor-responsive copper-activated disulfiram for synergetic nanocatalytic tumor therapy

Two birds with one stone: Copper metal-organic framework as a carrier of disulfiram prodrug for cancer therapy

Buffet-style Cu(II) for enhance disulfiram-based cancer therapy

V9302-loaded copper-polyphenol hydrogel for enhancing the anti-tumor effect of disulfiram

Disulfiram Copper Nanoparticles Prepared with a Stabilized Metal Ion Ligand Complex Method for Treating Drug-Resistant Prostate Cancers.

A CD44-targeted Cu(ii) delivery 2D nanoplatform for sensitized disulfiram chemotherapy to triple-negative breast cancer

In situ triggering antitumor efficacy of alcohol-abuse drug disulfiram through Cu-based metal-organic framework nanoparticles

Disulfiram: A Food and Drug Administration-approved multifunctional role in synergistically drug delivery systems for tumor treatment

Active-transporting of charge-reversal Cu(II)-doped mesoporous silica nanoagents for antitumor chemo/chemodynamic therapy

Sphingomyelin-based PEGylation Cu(DDC) 2 Liposomes Prepared via the Dual Function of Cu 2+ for Cancer Therapy: Facilitating DDC Loading and Exerting Synergistic Antitumor Effects

Smart Responsive Nanoplatform Via in Situ Forming Disulfiram-Copper Ion Chelation Complex for Cancer Combination Chemotherapy

Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems

A cascade nanoplatform for intelligent response to tumor microenvironment and collaborative cancer therapy

A Cascade Nanoplatform for the Regulation of the Tumor Microenvironment and Combined Cancer Therapy.

Tumor specific in situ synthesis of therapeutic agent for precision cancer therapy

Coordinating effect of ferroptosis and in situ disulfiram toxification for enhanced cancer therapy

Biomineralized nanomedicine for enhanced cancer therapy through in situ toxification and amplified Ca 2+ overload